Dissecting TSC2-mutated renal and hepatic angiomyolipomas in an individual with ARID1B-associated intellectual disability

Bernt Popp¹, Abbas Agaimy², Cornelia Kraus¹, Karl X. Knaup³, Arif B. Ekici¹, Steffen Uebe¹, André Reis¹, Michael Wiesener³ and Christiane Zweier¹*

Abstract

Background: Several subunits of the SWI/SNF chromatin remodeling complex are implicated in both cancer and neurodevelopmental disorders (NDD). Though there is no clinical evidence for an increased tumor risk in individuals with NDDs due to germline mutations in most of these genes so far, this has been repeatedly proposed and discussed. A young woman with NDD due to a de novo mutation in ARID1B now presented with a large renal (>19 cm in diameter) and multiple hepatic angiomyolipomas (AMLs) but no other signs of tuberous sclerosis complex.

Methods: We analyzed tumor and healthy tissue samples with exome and panel sequencing.

Results: Additionally to the previously known, germline ARID1B variant we identified a post-zygotic truncating TSC2 variant in both renal and hepatic AMLs but not in any of the healthy tissues. We did not detect any further, obvious tumor driver events. The identification of a passenger variant in SIPA1L3 in both AMLs points to a common clonal origin. Metastasis of the renal AML into the liver is unlikely on the basis of discordant histopathological features. Our findings therefore point to very low-grade mosaicism for the TSC2 variant, possibly in a yet unknown mesenchymal precursor cell that expanded clonally during tumor development. A possible contribution of the germline ARID1B variant to the tumorigenesis remains unclear but cannot be excluded given the absence of any other evident tumor drivers in the AMLs.

Conclusion: This unique case highlights the blurred line between tumor genetics and post-zygotic events that can complicate exact molecular diagnoses in patients with rare manifestations. It also demonstrates the relevance of multiple disorders in a single individual, the challenges of detecting low-grade mosaicisms, and the importance of proper diagnosis for treatment and surveillance.

Keywords: ARID1B, TSC2, Tuberous sclerosis complex, Neurodevelopmental disorders, Angiomyolipoma, Mosaic
their molecular cause revealed a post-zygotic stop-variant in \textit{TSC2} in addition to the previously known germline variant in \textit{ARID1B}.

**Methods**

**Clinical report**

This individual had been reported previously (patient 5) when the de novo variant c.3304C $>$ T, p.(Arg1102*) in \textit{ARID1B} (NM_020732.3) was identified to be causative for her intellectual disability \cite{2}. Clinical details up to 12 years 8 months are described elsewhere \cite{2}. At age 19 she had moderate cognitive impairment with good comprehension, speaking in two-word sentences and friendly behavior. After indicating abdominal pain, examination by ultrasound and computer tomography (CT) revealed a large (diameter 19 cm) tumor in the left kidney and multiple liver tumors (> 8, average diameter ca. 2 cm) (Fig. 1a-c). Histological investigation after nephrectomy and removal of one of the liver tumors confirmed them to be AMLs (Fig. 1d-f). Subsequent cranial MRI (magnetic resonance imaging), ultrasound of the right kidney and detailed skin and nail examination did not reveal any further clinical features of tuberous sclerosis complex such as subependymal nodules or cortical dysplasia, skin lesions or ungual fibromas. Apart from two single seizures in early infancy she had no history of epilepsy. Meanwhile, cardiological evaluation and computer tomography of the lung did not reveal further anomalies.

**DNA extraction and sequencing**

DNA from peripheral blood lymphocytes (PBL) was extracted by standard procedures. DNA from cultured fibroblasts (obtained from a cleft palate surgery specimen) and from renal tubular cells grown from a urine specimen of the remaining healthy kidney as described by others \cite{9} were extracted using the Qiagen DNAeasy system according to manufacturer’s recommendations (Qiagen, Hilden, Germany).

Genomic DNA from marked tumor and neighboring non-neoplastic tissues was extracted from 5 $\mu$m sections. After de-paraffinization the NucleoSpin Tissue kit was used according to the manufacturer’s protocol (Macherey-Nagel, Düren, Germany), and subsequently lysis with proteinase K at a concentration of 0.8–1.0 U per digest.

![Fig. 1 Renal and hepatic AMLs](image-url)

\textbf{a} Abdominal CT scan showing the large AML of the left kidney. \textbf{b} CT of the liver showing three lesions indicated by arrows. \textbf{c} Macroscopic picture of the renal AML. \textbf{d} Histopathology with haematoxylin and eosin (HE) staining showing blood vessels lacking elastic tissue ("angio"), smooth muscle cells ("myo") and adipose tissue ("lipoma") close together as a typical sign of angiomyolipoma. \textbf{e} HE staining of a region from the large kidney AML showing the ordinary smooth muscle differentiation and rhabdoid/epithelioid cell features. \textbf{f} HE staining of a region from the resected hepatic AML, being composed mainly of fat cells.
at 55 °C overnight was performed. Exome sequencing of DNA from blood, renal and liver tumor was performed on an Illumina HiSeq 2500 system (Illumina, Inc., San Diego, USA) after enrichment with the SureSelect Target Enrichment v6 technology (Agilent Technologies, Santa Clara, CA). Sequencing of DNA from unaffected renal and hepatic tissues and from fibroblasts and renal tubular cells was performed on an Illumina MiSeq system using the TruSight Cancer panel. Complete coverage (>20x) for \( TSC1 \) (NM_000368.3) and \( TSC2 \) (NM_000548.3) was ensured. MLPA analysis for \( TSC1 \) and \( TSC2 \) on PBL DNA was performed using the kits P046 and P124 from MRC-Holland (Amsterdam, The Netherlands). Variants in \( TSC2 \) and \( SIPA1L3 \) (NM_015073.2) were validated by Sanger sequencing using standard procedures.

Resulting sequencing reads were aligned and processed as described previously [10]. Concurrent variant calling of the two AML and the PBL exome BAM files together with 13 control samples from the same machine run was performed using freebayes version 1.1.0 [11]. SnpEff/SnpSift version 4.3p [12] with dbNSFP [13] was used for annotation. Potential somatic variants at coding and splice region positions from the freebayes calls were filtered to have an alternative allele fraction (AF) ≤1% in blood and of ≥5% in the respective tumor. Only sites with a read coverage of ≥10 in each sample and with ≥5 alternative allele reads in the tumor were considered. Additionally, variants present with an allele depth of ≥2x in 13 in-house controls from the same run were excluded. Copy number variation (CNV) screening from exome data was done with CNVkit version 0.9.4.dev0 [14]. BAM files were then visually inspected at regions of interest using the IGV browser version 2.4.7 [15, 16].

**Results**

Analysing exome data from blood and renal and hepatic AMLs showed the known variant in \( ARID1B \), as expected, in about 50% of the reads, respectively (Fig. 2a and Additional file 1: Figure S1). No further pathogenic variant in \( ARID1B \), nor loss of heterozygosity (LOH) was observed in tumor tissues (Additional file 1: Figures S2 and S3). Analysis of \( TSC1 \) and \( TSC2 \) revealed the
pathogenic variant c.3099C > G, p.(Tyr1033*) [17] in TSC2 (NM_000548.4) in 67.3% (270/401) of the reads in DNA from the renal and in 41.2% (49/119) of reads from the hepatic AML, while it was not detected in any of the 179 reads from blood (Fig. 2a and Additional file 1: Figure S1). Panel sequencing on DNA from unaffected renal and liver tissues and from fibroblasts did not detect the TSC2 variant in any of the 31 to 508 reads, respectively (Fig. 2a and Additional file 1: Figure S4), but in one of 1210 reads in DNA from tubular cells. However, given its location at the beginning of the read and as it occurred in only one read in an overlapping read pair, it most likely represents an artefact (Fig. 2a and Additional file 1: Figure S5).

Searching exome data for additional variants in renal or hepatic AML and absent in blood revealed a variant in SIPA1L3 (c.187_192dup, p.(Ala63_Thr64dup) (NM_015073.2); COSM5959440), which was additionally excluded by Sanger sequencing in DNA from fibroblasts and healthy renal and hepatic tissues. Dysfunction of SIPA1L3 has been discussed as a possible contributor to the phenotype of some malignancies as it led to abnormalities of epithelial cell morphogenesis, cytoskeletal structure and adhesion in a colorectal adenocarcinoma cell line and as somatic SIPA1L3 alterations were found in various, mainly epithelial cancer types [18, 19]. However, it has not yet been reported as a tumor driver (20 and Cosmic Cancer Gene Census (CGC)), and it was not found to be mutated in a study searching for additional somatic mutations in TSC-related lesions [21]. Therefore, we consider this variant most likely a passenger variant, though we cannot exclude a contributing effect in the tumor pathogenesis in our patient. Copy number analysis from exome data indicated a possible deletion of TSC2 in a subpopulation of tumor cells. However, analysis of heterozygous variant positions at this locus did not show a significant deviation from 0.5, therefore not supporting validity of this finding (Additional file 1: Figures S2 and S3 and Additional file 2). These analyses are challenged by variability in exome data (e.g. coverage uniformity) and compromised tumor purity. No other large regions of LOH or CNVs were detected in the kidney or liver AMLs, indicating a relatively stable constellation in both tumors (Additional file 1: Figures S2 and S3; Additional file 2).

**Discussion**

Tuberous Sclerosis Complex (TSC; OMIM #191100, *605284, #613254, *191092) is a multisystemic disorder generally caused by germline variants in TSC1 or TSC2. Multiple renal and extra-renal angiomyolipomas (AMLs) represent one of the characteristic manifestations of TSC. Renal AMLs are commonly observed in 80% of patients, while hepatic AMLs are less frequent and occur in ca. 13% of affected individuals [22]. When renal and hepatic AMLs were detected in the herewith reported individual with ARID1B associated NDD and without other frequent and typical signs of TSC, we considered various possibilities: a) The AMLs might be causally related to the germline ARID1B mutation. b) The AMLs represent a mild and atypical manifestation of TSC in the sentence of multiple diagnoses as reported recently in a large study that revealed aberrations in two or more disease loci in 4.9% of 7374 individuals with various phenotypes tested by clinical exome sequencing [23]. Or c) Another cause, un-related to the known ARID1B variant and not necessarily deducible from the AML phenotype might be responsible for the unusual presentation.

When performing exome sequencing on DNA from the renal and hepatic AMLs, we found no indication for a contribution of ARID1B or other commonly cancer-related genes such as TP53 to their genesis. While exome sequencing on blood did not detect a variant in the TSC genes TSC1 or TSC2, we detected the same pathogenic TSC2 variant in both renal and hepatic tumor tissues. This and an additional variant in SIPA1L3 also exclusively found in both AMLs underline their common clonal origin and open two possibilities: a) the multiple hepatic AMLs being metastases from the huge renal AML as rarely reported particularly for epithelioid AMLs [24], or b) the AMLs resulting from a low-grade mosaicism for the TSC2 variant. The first possibility seems extremely unlikely based on the discordant histopathological features of the AMLs. The huge renal tumor was predominantly composed of epithelioid cells entrapping only a very minor fatty component. In contrast, the resected hepatic AML was almost devoid of such epithelioid cells and was composed almost exclusively of fat cells closely mimicking a lipoma. Further supporting the second possibility, mosaicism has been frequently observed for TSC2 variants, including low-grade mosaicism with allele frequencies < 1% or variants only detected in skin tumor biopsies but not in blood or saliva [25].

Of note, we did not reliably observe the TSC2 variant in any of the sequencing reads from unaffected kidney, unaffected liver, fibroblasts or renal tubular cells, which might be expected in case of mosaicism. Given that the lesional cell of these TSC-related mixed neoplasms, the so-called “perivascular epithelioid cell” (PEC) has no known physiological counterpart, renal and hepatic AMLs might have their origin in a common, yet unknown mesenchymal precursor cell that expanded clonally during tumor development [26]. This has previously been discussed for the co-occurrence of sporadic pulmonary lymphangioleiomyomatosis and renal AMLs with somatic TSC2 variants [27] and for TSC-associated AMLs [28]. Presence of the TSC2 variant in only very few tumor precursor cells
might therefore hinder detection in healthy tissues even by next-generation-sequencing (overview in Fig. 2b).

In contrast to many other tumors, AMLs are genetically relatively stable, and bi-allelic loss of TSC2 has been postulated as a sufficient and the main driver for AML development [28]. Given the absence of a second TSC2 variant, TSC2-LOH or any other evident tumor driver apart from the unclear variant in SIPA1L3 in the renal and hepatic AMLs of the herewith reported individual, a contribution of the germline ARID1B variant to the tumorigenesis cannot be excluded.

In any case, identifying the TSC2 variant in the herewith reported individual has important consequences for her medical care. It now prompts TSC specific surveillance including regular echocardiograms, high-resolution computed tomography of the lung and brain MRIs in addition to regularly checks of the remaining kidney and the liver. As mTOR inhibitors have been proven to be an efficient therapy in TSC [29], this treatment option will be evaluated and discussed based on her future disease course and manifestations.

Despite a good sequencing depth of 179 reads the TSC2 variant was not detectable in blood, meaning that it also would not have been detected as an incidental finding when performing exome sequencing because of the NDD and thus would not have resulted in predictive counseling and surveillance procedures. Proper medical care in individuals with mental handicap is often challenging due to limited expression of medical discomfort and thus missed co-morbidities or health complications unrelated to the initial diagnosis.

Conclusion
Next to the value of combining genetic and pathologic findings, this unique case demonstrates and emphasizes several generally important aspects of genetic and medical care such as a) considering multiple (independent) diagnoses in a single individual, b) considering mosaicism or post-zygotic variants and taking the efforts to detect them, as c) a proper diagnosis might have important consequences on treatment and surveillance. These efforts can be challenged by potential mosaicism in multi-tumor syndromes where the mutation-carrying cell of origin is still unknown and might represent a very minor yet unidentifiable cell population leading to false-negative results.

Additional files

**Additional file 1:** Figure S1. IGV snapshots from exome sequencing. Figure S2. Copy number analysis from exome data from the kidney AML using CNVkit. Figure S3. Copy number analysis from exome data from the liver AML using CNVkit. Figure S4. IGV snapshots from targeted Cancer Panel and Sanger sequencing. Figure S5. IGV snapshot of the artefact read identified in tubulus cells. (DOCX 1912 kb)

**Additional file 2:** Exome CNV calls and heterozygous SNPs in the ARD1B or TSC2 region. Microsoft Excel spreadsheet file containing the worksheets "summary", "CNVkit_exome-aberrations" and "LOH_ARID1BandTSC2". The "summary" worksheet contains a detailed description of all other worksheets and the respective data columns. The "CNVkit_exome-aberrations" worksheet contains all the segments called by CNVkit 0.9.4.dev0 which have a copy number different from 2. The "LOH_ARID1BandTSC2" worksheet contains all heterozygous single nucleotide variants called in the PBL and both kidney and liver AML samples with at least 20 bp coverage in each sample (to reduce sampling bias) with 500 k bases of the ARD1B (chr6[hg19]:156599064–158,031,913) or TSC2 (chr16[hg19]:159,799,902–2,638,713) gene. Fisher’s exact test from R version 3.4.3 was used to calculate p-values between the PBL and AML read coverages at each SNP position to check for significant deviation from the expected allele fraction. (XLSX 48 kb)

**Abbreviations**
AML: Angiomyolipoma; CNV: Copy number variant; LOH: Loss of heterozygosity; MRI: Magnetic resonance imaging; NDD: Neurodevelopmental disorder; PBL: Peripheral blood lymphocytes; PEC: Perivascular epithelioid cell; SWI/SNF: SWItch/Sucrose Non-Fermentable; TSC: Tuberous sclerosis complex

**Acknowledgements**
The authors would like to thank the family for participating and supporting this study. We thank Leonora Klassen, Antje Serworota, Heike Friebel and Natasha Leicht for excellent technical assistance.

**Funding**
CZ was supported by grants from the German Research Foundation (DFG, ZW184/1–2, ZW184/3–1 and GRK2162) and by the Interdisciplinary Center for Clinical Research (IZKF) Erlangen (E26). A.R. was supported by the German Ministry of Education and Research (BMBF, grant numbers: 01GS08160, 01GM1320A (Chromatin-Net) and the IZKF Erlangen (E16). We acknowledge support by Deutsche Forschungsgemeinschaft and Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) within the funding programme Open Access Publishing.

**Availability of data and materials**
The datasets generated and/or analysed during the current study are not publicly available due to individual privacy regulations but are available from the corresponding author on reasonable request.

**Authors’ contributions**
BP and CZ conceived the study. AA prepared and analyzed the histological sections. MW and CZ provided patients’ data and performed clinical assessments. KXK and MW provided the renal tubular cells. BP, SU, AE, CK and AR, and CZ analyzed and interpreted the molecular data. BP and CZ wrote and edited the manuscript with input from all co-authors. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**
The study was approved by the ethical review board of the Friedrich-Alexander-Universität Erlangen-Nürnberg (Ref. No. 253_15B). Informed written consent for publication of clinical details was obtained from the patient’s legal guardian.

**Consent for publication**
Written consent for publication of clinical details was obtained from the patient’s legal guardian.

**Competing interests**
The authors declare that they have no competing interests.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**
1Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabacheranlage 10, 91054 Erlangen, Germany.
References

1. Deciphering Developmental Disorders. S. Prevalence and architecture of de novo mutations in developmental disorders. Nature. 2017;542(7642):433–8.

2. Hoyer J, Eckii AB, Endele S, Popp B, Zweier C, Wiesener A, Wohlleber E, Dudke A, Rossei E, Petch C, et al. Haplinsufficiency of ARID1B, a member of the SWI/NSF-a chromatin-remodeling complex, is a frequent cause of intellectual disability. Am J Hum Genet. 2012;90(3):565–72.

3. Tsurusaki Y, Okamoto N, Hiroshi T, Ikoma Y, Hibi-Ko Y, Kaname T, Naitomi K, Kawame H, Waku K, et al. Mutations affecting components of the SWI/NSF complex cause cofin-Sritis syndrome. Nat Genet. 2012;44(4):373–8.

4. Santen GW, Aten E, Sun Y, Almomani R, Gilissen C, Nielsen M, Kant SG, Snoeck IN, Peeters EA, Hilsfrool-Horstey, et al. Mutations in SWI/NSF chromatin remodeling complex gene ARID1B cause cofin-Sritis syndrome. Nat Genet. 2012;44(8):379–80.

5. Wilson SG, Roberts CW. SWI/NSF nucleosome remodelers and cancer. Nat Rev Cancer. 2011;11(7):481–92.

6. Holischen A, Krumm N, Eichler EE. Prioritization of neurodevelopmental disease genes by discovery of new mutations. Nat Neurosci. 2014;17(6):764–72.

7. Santen GW, Aten E, Vulo-van Silfhout AT, Pottinger C, van Bon BW, van Minderhout U, Snowdowone r, van der Lans CA, Boogard M, Linsens MM, et al. Coffin-Sirius syndrome and the BAF complex: genotype-phenotype study in 63 patients. Hum Mutat. 2013;34(11):1519–28.

8. Agaimy A, Foulkes WD. Hereditary SWI/SNF complex deficiency syndromes. Semin Diagn Pathol. 2018.

9. Zhou T, Benda C, Dunzinger S, Huang Y, Ho JC, Yang J, Wang Y, Zhang Y, Zhuang Q, Li Y, et al. Generation of human induced pluripotent stem cells from urine samples. Nat Protoc. 2012;7(12):2800–9.

10. Hauer NN, Popp B, Schoeller E, Schuhmann S, Heath KE, Hisado-Oliva A, Popp et al. BMC Cancer (2019) 19:435

11. Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. arXiv preprint arXiv:1207.3907. 2012.

12. Cingolani P, Patenel M, Coon M, Nguyen T, Land S, Ruden DM, Lu X. Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift. Front Genet. 2012;3:335.

13. Liu X, Jian X, Boerwinkle E. dbNSFP v2.0: a database of human nonsynonymous SNVs and their functional predictions and annotations. Hum Mutat. 2013;34(9):E2393–402.

14. Tulevich E, Shain AH, Botton T, Bastian BC. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 2016;12(4):e1004873.

15. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24–6.

16. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14(2):78–92.

17. Dabara SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung A, Choy YS, Reeve MP, Thiele E, Egellhoff JC, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68(1):64–80.

18. Greenlees R, Mihelec M, Yousof S, Speidel D, Wu SK, Rinkwitz S, Prokudin I, Perveen R, Cheng A, Ma A, et al. Mutations in SIPA1L3 cause eye defects with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68(1):64–80.

19. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksyov BA, Jacobsen A, Byrne CJ, Heuer ML, Larson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.

20. Tamborero D, Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Kandoth C, Reimand J, Lawrence MS, Getz G, Bader GD, Ding L, et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep. 2013;3:2650.

21. Martin KR, Zhou W, Bowman MJ, Shih J, Au KS, Dittenhafer-Reid KE, Sisson KA, Koeeman J, Weiensberger DJ, Cottingham SL, et al. The genomic landscape of tuberous sclerosis complex. Nat Commun. 2017;8:15816.

22. Fricke BL, Donnelly LF, Casper KA, Biskler JJ. Frequency and imaging appearance of hepatic angiomyolipoma in pediatric and adult patients with tuberous sclerosis. AJR Am J Roentgenol. 2004;182(4):1027–30.

23. Posey J, Harel T, Liu P, Rosenfeld JA, James RA, Coban Akdemir ZH, Walkiewicz M, Bi W, Xiao R, Ding Y, et al. Resolution of disease phenotypes resulting from multiclonal genomic variation. N Engl J Med. 2017;376(1):121–31.

24. He W, Cheville JC, Sadow PM, Gopalan A, Fine SW, Al-Ahmadi HA, Chen YB, Oliva E, Russo P, Reuter VE, et al. Epithelioid angiomyolipoma of the kidney: pathological features and clinical outcome in a series of consecutively resected tumors. Mod Pathol. 2013;26(10):1355–64.

25. Tybusczy ME, Dies KA, Glass J, Camposano S, Chekaluk Y, Thorner AR, Lin L, Krueger D, Franz DN, Thiele EA, et al. Mosaic and Intronic mutations in TSC1/TSC2 explain the majority of TSC patients with no mutation identified by conventional testing. PLoS Genet. 2015;11(11):e1005637.

26. Bonetti F, Pea M, Martignoni G, Doglioni C, Zamboni G, Capelli P, Rimondi P, Andrion A. Clear cell (“sugar”) tumor of the lung is a lesion strictly related to angiomyolipoma—the concept of a family of lesions characterized by the presence of the perivascular epithelioid cells (PEC). Pathology. 1994;26(3):230–6.

27. Casillo T, Atrashidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA. 2000;97(11):6085–90.

28. Giannikou K, Malinovska IA, Pugh TJ, Yan R, Tseng YY, Oh C, Kim J, Tybusczy ME, Chekaluk Y, Liu Y, et al. Whole exome sequencing identifies TSC1/TSC2 Biallelic loss as the primary and sufficient driver event for renal angiomyolipoma development. PLoS Genet. 2016;12(8):e1006242.

29. Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC, Howe CJ, Doyle T, Pointron K, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17(12):4071–81.